Bilateral amygdala damage has been linked with an inability to recognise facial expressions of emotion, particularly the expression of fear. Patients with Alzheimer’s disease (AD) suffer from atrophy of the amygdala at an early stage of the disease. It was therefore predicted that AD patients would have more difficulty in two tasks of processing facial expressions of emotion. Thirteen patients diagnosed with probable AD referred to the Oxford Project to Investigate Memory and Ageing (OPTIMA) and 13 age-matched controls enrolled in the programme participated in the study. Participants were shown two tasks, one involved recognising and labelling a target expression, the other matching a target expression with one of four others. The results showed that compared with the controls, the patients were not impaired in recognising any facial expressions of emotion in the labelling task, but were impaired in matching three facial expressions of emotion in the second task. It was speculated that the impairment in the matching task could have been a result of visuospatial dysfunction rather than one of processing emotions.

Keywords:
Alzheimer’s disease, Facial expressions, Amygdala
This content is only available via PDF.
© 2004 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.